Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 70

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 70
---
 private placement warrants and the shares of common stock issuable upon the exercise of the private placement warrants
are not transferable, assignable or salable until after the completion of a Business Combination, subject to certain limited exceptions,
and none of the private placement warrants will be redeemable by the Company so long as they are held by their initial purchasers or their
permitted transferees.

In the event the Company determines to redeem the warrants, holders
of our redeemable warrants would be notified of such redemption as described in the Warrant Agreement. Specifically, in the event that
the Company elects to redeem all of the redeemable warrants as described above, the Company will fix a date for the redemption (the “Redemption
Date”). Notice of redemption will be mailed by first class mail, postage prepaid, by the Company not less than 30 days prior
to the Redemption Date to the registered holders of the redeemable warrants to be redeemed at their last addresses as they appear on
the registration books. Any notice mailed in the manner provided in the Warrant Agreement will be conclusively presumed to have been
duly given whether or not the registered holder received such notice. Accordingly, if a holder fails to actually receive the notice of
or otherwise fails to respond on a timely basis, it could lose the benefit of being a holder of a Company public warrant.

The closing price of the Company’s common stock has not exceeded
$16.50 per share for any of the 30 trading days prior to the date of this proxy statement/prospectus.

Risks Related to the Company Business and Operations

The following risk factors reference the risks and uncertainties
relating to the business and operations of OSR, which, following the closing of the Business Combination, are the business and operations
of the Company. References in this section to “we,” “us,” and “our” refer to OSR prior to the closing
of the Business Combination and to the Company after closing.

37

The Company’s limited operating history, the early stage
of its development programs and the inherent uncertainties and risks involved in pharmaceutical product development may make it difficult
for it to execute on its business model.

We are a global drug development company with a limited operating history
upon which you can evaluate our business and prospects. Our operations to date have been limited to organizing and staffing our company,
business planning, raising capital, acquiring our portfolio companies, establishing our intellectual property portfolio and performing
research and development in support of our product candidates. We